Welcome to our dedicated page for Inogen news (Ticker: INGN), a resource for investors and traders seeking the latest updates and insights on Inogen stock.
News for Inogen Inc (INGN) centers on its activities as a medical technology company focused on respiratory products for homecare use. This page aggregates company press releases, earnings announcements, product launches, and other public updates that Inogen provides to investors, patients, and partners.
Inogen regularly issues quarterly financial results and outlook updates, detailing revenue by sales and rental categories, business-to-business and direct-to-consumer performance, gross margin trends, operating expenses, and non-GAAP measures such as EBITDA and adjusted EBITDA. These releases often highlight factors driving performance, such as demand from domestic and international business-to-business customers and changes in direct-to-consumer and rental revenue.
Product-related news is another key theme. Recent announcements include the launch of the Voxi 5 stationary oxygen concentrator, designed to expand access to oxygen therapy for long-term care patients in the United States, and the introduction of Aurora CPAP masks for patients with obstructive sleep apnea. Such updates illustrate how Inogen is broadening its respiratory care portfolio beyond portable oxygen concentrators into stationary oxygen therapy and sleep-therapy accessories.
Corporate and leadership developments, such as technology and executive appointments, also appear in Inogen’s news flow, offering context on how the company is organizing around digital health, connected devices, and operational execution. Investors and observers can use this news page to follow Inogen’s financial trajectory, portfolio evolution, and strategic priorities in home respiratory and sleep care.
For anyone tracking INGN stock, revisiting this page provides a consolidated view of Inogen’s latest earnings releases, conference call announcements, and product milestones, all drawn from the company’s own public communications.
Inogen, Inc. (NASDAQ: INGN) has announced a partnership with Ashfield Healthcare to enhance its sales capabilities by adding around 20 dedicated sales representatives to its prescriber sales organization. The collaboration aims to improve market penetration for portable oxygen concentrators (POCs) and leverage Ashfield's proprietary insights and analytics tools to drive clinician sales performance. CEO Nabil Shabshab emphasized the importance of increasing collaboration with healthcare prescribers to enhance awareness of Inogen’s offerings. This strategy is expected to positively impact patient service in oxygen therapy.
Inogen, Inc. (NASDAQ: INGN) reported a 41.7% increase in second-quarter 2021 revenue, reaching $101.6 million, driven by strong consumer demand and improved pricing. Domestic direct-to-consumer revenue rose 35.6% to $40.9 million, while rental revenue soared 85.2% to $11.3 million. However, the company faces supply chain challenges, particularly due to semiconductor shortages, which are expected to constrain revenue growth and increase costs. As of June 30, 2021, Inogen had $250 million in cash with no debt and anticipates a net loss in the second half of 2021 due to these challenges.
Inogen, Inc (Nasdaq: INGN) will release its second quarter 2021 financial results on August 4, 2021, after market close. A conference call will follow at 1:30pm PT/4:30pm ET to discuss the results. Interested participants can join by calling (877) 841-3961 for domestic or (201) 689-8589 for international access. A replay will be available from August 4, 2021, 3:30pm PT until August 18, 2021. The company focuses on developing and marketing portable oxygen concentrators for chronic respiratory patients.
Inogen has appointed Jason Somer as the new Executive Vice President and General Counsel, effective July 12, 2021. CEO Nabil Shabshab emphasized that Somer's 25 years of legal experience will enhance Inogen's legal and compliance functions, crucial for the company's growth strategy. Somer expressed his commitment to increasing stockholder value while leading the legal organization. His previous roles include serving as head legal counsel at Invoca, and he holds advanced degrees in law and biology.
Inogen, Inc. (NASDAQ: INGN) has appointed Dr. Stanislav Glezer as Executive Vice President and Chief Medical Officer, effective June 21, 2021. CEO Nabil Shabshab expressed confidence that Dr. Glezer's over 25 years of experience in clinical research and medical affairs will enhance Inogen's clinical capabilities and market development efforts. Dr. Glezer aims to lead Medical Affairs, Clinical Research, and Regulatory organizations to improve patient outcomes through clinical evidence collaboration. His previous roles include significant positions at Becton, Dickinson and Company, and Novo Nordisk.
Inogen, a medical technology company, has appointed Elizabeth (Beth) Mora to its Board of Directors, effective May 24, 2021. Mora, a seasoned executive with extensive financial expertise, fills the vacancy left by R. Scott Greer, who resigned from the board. She will also serve on the Audit Committee. CEO Nabil Shabshab expressed confidence in Mora's ability to enhance strategic initiatives aimed at increasing patient access to oxygen therapy products. The board transition aims to strengthen governance and support Inogen's growth objectives, scheduled for review at the 2024 annual meeting.
Inogen, Inc. (NASDAQ: INGN), a leader in respiratory health technologies, will present at the 41st Annual William Blair Virtual Growth Stock Conference on June 3rd, 2021, at 4:00 p.m. CDT. CEO Nabil Shabshab and CFO Alison Bauerlein will lead the presentation, which can be accessed via the company's Investor Relations page. This presentation highlights Inogen's commitment to innovation in portable oxygen concentrators, enhancing care options for patients with chronic respiratory conditions.
Inogen, Inc. (NASDAQ: INGN) reported Q1 2021 revenue of $86.9 million, a 1.8% decline from Q1 2020, largely due to COVID-19 impacts. Domestic business-to-business revenue rose 11.6% to $30.7 million, while rental revenue surged 84.2% to $9.9 million. As of March 31, 2021, cash and equivalents totaled $233.2 million, with no debt. Operating loss was $2.1 million, and net loss was $0.7 million. The company refrained from providing full-year guidance for 2021 due to pandemic uncertainties, while anticipating increased operational expenses as it invests in growth initiatives.
Inogen, a medical technology company focused on respiratory products, will announce its first quarter 2021 financial results on May 4, 2021, after market close. A conference call will follow at 1:30 PM PT/4:30 PM ET, with a replay available until May 18, 2021. Investors can listen live via phone or through Inogen's Investor Relations website. The company specializes in portable oxygen concentrators for patients with chronic respiratory conditions.
Inogen, Inc. (NASDAQ: INGN) announced the appointment of George Parr as Executive Vice President and Chief Commercial Officer, effective April 12, 2021. This follows the planned departure of Byron Myers and Arron Retterer, effective June 4, 2021. Inogen expects first-quarter 2021 revenue to range from $84.0 million to $87.0 million, based on preliminary estimates. Parr brings over 25 years of experience in the medical technology sector, which the company hopes will enhance growth and patient access to its products. The leadership changes aim to strengthen Inogen’s market position.